On 19 November 2026 the Union Health Ministry published a package of draft amendments to the Drugs Rules, 1945, and one of them changes something buyers have never been able to check before: how a medicine was stored and moved after it left the factory. The proposal folds Good Storage and Distribution Practices (GSDP) — a CDSCO guidance framework — directly into the Drugs Rules.
For anyone buying Indian generics, whether from a pharmacy counter in Delhi or a distributor in Lagos, this is the most consequential regulatory shift of the quarter. Until now, a clean WHO-GMP certificate only told you the product was made well. It said nothing about the eleven months it spent in a hot warehouse. This guide explains what GSDP actually covers, how to use it as a buying filter, and what still is not fixed.
📦 What the Ministry Actually Proposed on 19 November 2026
The ministry issued several separate draft notifications in one package. The core GSDP proposal is distinct from the others, and buyers should understand the whole set because they interact.
- GSDP incorporated into the Drugs Rules, 1945 — the headline change. The framework builds on CDSCO’s own GSDP guidance and is proposed to cover procurement, purchasing, storage, distribution, transportation, documentation and record-keeping, so that product quality and identity are protected at every stage of the distribution chain, from manufacturer or importer to the point of supply to the patient. As reported by The New Indian Express and ETV Bharat on 19 November 2026.
- A separate wholesale licensing regime for bulk drugs, APIs and key starting materials (KSMs) — a dedicated application form for bulk-drug wholesale licences, ending the current arrangement where one wholesale licence covers both formulations and raw materials. Business Standard reported the draft notification as dated 18 November 2026.
- Antimicrobials brought into the definition of a “new drug” under the New Drugs and Clinical Trials Rules, 2019 — which would move approval of antibiotics, antivirals and antifungals from state authorities to the Central Licensing Authority, with bioavailability, bioequivalence and stability data required.
- Limited relief under the revised Schedule M for medicinal gases, empty gelatin capsules and disinfectant fluids — restoring exemptions these categories held before the revised Schedule M was notified via G.S.R. 922(E) on 28 December 2023, on the recommendation of the Drugs Technical Advisory Board at its 93rd meeting on 16 February 2026.
Note the dates carefully: the ministry’s own statement was issued on 19 November, but the underlying drafts carry earlier dates — 6 November for the Schedule M and antimicrobial drafts, 18 November for the bulk-drug licensing draft. Draft dates and publication dates frequently diverge on Indian regulatory instruments, and a buyer tracking a rule from press coverage alone can easily be a fortnight out.
🔍 The Six Risk Categories GSDP Is Built To Catch
This is the most useful part of the proposal for a buyer, because the ministry named the failure modes explicitly. Its stated objective is to address risks in the handling and movement of products across the supply chain, specifically:
- Deterioration — chemical or physical degradation from heat, light, humidity or time.
- Contamination — ingress of microbial, chemical or particulate matter during handling.
- Mix-ups — one product or strength being confused with another during storage or picking.
- Falsification — counterfeit or mislabelled product entering a legitimate chain.
- Diversion — product moving outside its authorised channel, including export-only stock appearing domestically.
- Unauthorised distribution — sale by entities without the licence to do so.
Read that list against what actually goes wrong with imported generics and the mapping is uncomfortable. A batch that tests perfect at release and fails at the pharmacy counter is almost always a deterioration or mix-up story, not a manufacturing story. GSDP is the regulatory acknowledgment of that gap.
🧾 Who Becomes Accountable Under the Proposal
The ministry’s stated accountability chain is broad: manufacturers, importers, wholesalers, distributors, stockists and other entities involved in distribution. Practically, that means the responsibility for product quality no longer stops at the factory gate — it travels with the goods.
Two implications matter for buyers:
- Traceability becomes a document obligation, not a courtesy. The proposal explicitly promotes “robust documentation, record-keeping and traceability.” If a supplier cannot produce a storage and transport record, that is a compliance signal, not an administrative inconvenience.
- Inspection powers expand in practice. The ministry expects the framework to support “inspection and enforcement by Central and State drug-control authorities.” Buyers should assume that the paperwork they request will increasingly mirror what an inspector will request.
📋 The Buyer’s Checklist: Seven Questions That Now Have Regulatory Weight
Use these before placing a repeat order. Each maps to a duty the GSDP proposal is designed to impose on someone in the chain.
- “Show me your storage temperature record for this batch, for the full period it sat in your warehouse.” Continuous data, not a monthly summary. A gap in the log is the answer.
- “What is your excursion procedure when a logger breaches the range?” A supplier with no written procedure is relying on luck. Deterioration risk is concentrated in the exceptions.
- “Who physically receives, and who releases, stock?” Segregation of duties is the cheapest defence against mix-ups. One person doing both is a single point of failure.
- “Is your wholesale licence scoped to what you are selling me?” This question becomes sharper once bulk drugs and formulations split into separate licences — a supplier licensed for finished formulations is not automatically licensed for raw materials.
- “Can you trace this batch to the importer, and the importer to the manufacturer?” Diversion and falsification both hide in a break in that chain.
- “Is this stock domestic-supply or export-only?” Diversion of export-designated stock is one of the six named risks. Ask before it becomes your problem.
- “Will you put your storage and transport obligations in the purchase contract?” A compliance framework you cannot enforce commercially is advisory only.
For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory.
🌡️ Cold Chain and High-Risk Solvents: The Two Places This Bites Hardest
The GSDP proposal sits in a wider cluster of raw-material and distribution controls, and the two are connected. The bulk-drug licensing draft is explicitly framed around oversight gaps in raw-material supply chains, following the contamination episodes involving cough syrups. A Delhi-based pharmaceutical industry body executive told Business Standard that monitoring the supply chain and quality of high-risk solvents, including propylene glycol used in formulations, is now a necessity.
The dependency numbers make the point. India imports most of its bulk drugs from China, and relies heavily on imports for several critical products including Penicillin G, Amoxicillin and Rifampicin. When a supply chain is import-heavy and intermediated by a large, poorly mapped trader layer, distribution quality stops being a logistics detail and becomes a product-quality variable.
Cold-chain products — insulins, most vaccines, many biologics and injectables — are where the buyer’s downside is worst. A temperature excursion during distribution is usually invisible in the finished pack: the carton is intact, the seal is unbroken, and the assay result from the manufacturing batch is irrelevant to what is now in the box. This is precisely the class of harm GSDP is aimed at, and precisely where a buyer’s own questions carry the most weight.
⚠️ What the Proposal Does Not Fix
Being clear about the limits is part of reading a draft correctly. Three things buyers should not assume:
- It is a draft, not law. The ministry has invited objections and suggestions from stakeholders and the public. Comments go to the Under Secretary (Drugs), Health Ministry, or to drugsdiv-mohfw@gov.in, within 30 days of copies of the relevant Gazette being made available to the public. Nothing in the framework is enforceable until the final notification is issued and comes into force.
- Existing licensees get transition time. On the bulk-drug licensing change specifically, officials indicated existing licensees will have time to comply — requirements applying “upon expiry of their current retention period or 12 months after the final publication of the amendment, whichever is later,” per the draft notification as reported by Business Standard. Expect a window in which compliant and non-compliant distributors operate side by side.
- No public registry exists yet. There is currently no data on how many wholesale licences in India are exclusively for bulk drugs, according to an industry body executive quoted by Business Standard. The proposed framework is designed to create that visibility; it does not deliver it on day one. Until it does, a buyer still cannot independently verify a distributor’s scope from a public database.
[CITATION NEEDED] The precise number of bulk-drug traders the new licensing registry is intended to capture has been reported at different orders of magnitude by different outlets. Treat any specific figure you see quoted as unverified until the DCGI’s registry is actually published.
🔗 How This Fits India’s Wider Quality Architecture
GSDP is a distribution-layer addition to a stack that buyers already navigate. In sequence, the layers now read:
- Manufacturing — revised Schedule M (notified G.S.R. 922(E), 28 December 2023) and WHO-GMP certification at site level.
- Product approval — CDSCO new-drug permission, or state licensing for standard formulations; proposed to move toward central approval for antimicrobials.
- Raw materials — bulk-drug and API wholesale licensing, proposed to become a separate regime with its own competent-person supervision requirement.
- Distribution and storage — GSDP, the subject of this draft.
- Post-market — NSQ alerts, batch recall, and the pharmacovigilance reporting streams.
A buyer who only ever checks layer one is checking roughly a fifth of the chain. The November 2026 package is the ministry’s own admission that the other four fifths needed explicit rules.
✅ What To Do This Month
- Re-paper your top three suppliers. Ask questions 1, 4 and 5 from the checklist above in writing. The answers you get before the rules bite are far more informative than the ones you will get after.
- Add a storage-excursion clause to your purchase terms. Specify the permitted range, the record format, and who bears the cost of a documented breach.
- Audit your cold-chain items separately. They carry the largest gap between “manufactured correctly” and “delivered correctly.”
- File comments if you are a stakeholder. The 30-day window is open. Distributors and importers who will carry the new obligations have a direct interest in how “record-keeping” and “traceability” get defined.
- Track the final notification, not the press coverage. Watch for the gazetted version of these drafts; that is the text that will be enforced.
📚 Sources
Regulatory facts in this article are drawn from: The New Indian Express, “Centre proposes strict rules for storage and distribution of drugs” (Kavita Bajeli-Datt, 19 November 2026); ETV Bharat, “Health Ministry Proposes Changes to Drugs Rules, 1945 To Ease Regulations, Strengthen Pharma Supply Chain” (19 November 2026, covering G.S.R. 985(E) dated 6 November 2026 and the 93rd DTAB meeting of 16 February 2026); Business Standard, “Centre proposes separate wholesale licensing framework for bulk drugs” (Sanket Koul, 19 November 2026); Business Standard, “Centre proposes central approval for antimicrobials amid AMR concerns” (Sanket Koul, 19 November 2026); and News Desk Report, “Centre Proposes Prior Central Approval for Antimicrobial Manufacturing” (19 November 2026), for the comment-submission route and 30-day window.
For more information, contact IMSDA at contact@indiamedicine.org.
